The downregulation of MHC class II expression on tumor cells after anti-PD-1 therapy in this study may contribute to resistance to anti-PD-1 therapy because it evades LAG-3 axis-mediated immunosuppression but inhibits activation of antitumor immune responses mediated by CD4-positive T cells. Here, CD4 is linked to neoplasm.